Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan

Q: What insider transactions did Immunovant (IMVT) director Atul Pande report?

He exercised stock options for 1,500 shares at $8.43 and sold 1,500 shares at $39.80 . The transactions reflect an option exercise followed by an equivalent share sale on the same date, under a pre-arranged Rule 10b5-1 trading plan.

Q: How many Immunovant (IMVT) stock options does Atul Pande hold after this filing?

After exercising options for 1,500 shares , he is reported as holding 66,681 stock options of this award. This figure appears as the total derivative securities following the transaction for the Stock Option (right to buy) entry.

Q: Does Atul Pande have any indirect holdings of Immunovant (IMVT) shares?

Yes. The filing shows 20,000 Common Shares held indirectly by a trust . This position is reported as a holding entry with indirect ownership classified as “By Trust,” separate from his directly held securities.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Immunovant director Atul Pande exercised stock options for 1,500 shares of Common Stock at $8.43 per share and on the same date sold 1,500 shares at $39.80 per share. The option exercise involved a fully vested award and left 66,681 option shares outstanding. In addition, 20,000 Common Shares are held indirectly by a trust. All reported trades occurred under a Rule 10b5-1 trading plan adopted on December 26, 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,500 shares ($47K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Pande Atul

Role Director

Sold 1,500 shs ($60K)

Approx. gross sale proceeds $60K

Approx. exercise cost $13K

Approx. pre-tax spread $47K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^{F1, F2}	1,500	$0.00	$0.00
Exercise	Common Stock ^F1	1,500	$8.43	$13K
Sale	Common Stock ^F1	1,500	$39.80	$60K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 66,681 shares (Direct); Common Stock — 116,731 shares (Direct); Common Stock — 20,000 shares (Indirect, By Trust)

Footnotes (2)

F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
F2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Options exercised: 1,500 shares Option exercise price: $8.4300 per share Shares sold: 1,500 shares +4 more

7 metrics

Options exercised 1,500 shares Stock options converted into Common Stock on 2026-07-24

Option exercise price $8.4300 per share Conversion or exercise price for the Stock Option (right to buy)

Shares sold 1,500 shares Common Stock sale reported on 2026-07-24

Sale price $39.8000 per share Per-share price for the reported Common Stock sale

Options outstanding after exercise 66,681 shares Total derivative securities following the Stock Option transaction

Indirect trust-held shares 20,000 shares Common Stock held indirectly by trust as of this report

10b5-1 plan adoption date December 26, 2025 Date the reporting person adopted the Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 Plan, Stock Option (right to buy, fully vested, indirect ownership

4 terms

Rule 10b5-1 Plan financial

"Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted..."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (right to buy financial

"Security title reported as Stock Option (right to buy) with underlying Common Stock"

fully vested financial

"Reflects an award of stock options to purchase Common Shares that is fully vested"

indirect ownership financial

"Common Stock position reported with indirect ownership classified as By Trust"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/24/2026 - 05:59 PM Accepted by SEC EDGAR 07/24/2026 - 05:59 PM

FAQ

What insider transactions did Immunovant (IMVT) director Atul Pande report?

He exercised stock options for 1,500 shares at $8.43 and sold 1,500 shares at $39.80. The transactions reflect an option exercise followed by an equivalent share sale on the same date, under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Atul Pande trade Immunovant (IMVT) shares?

He effectively acquired shares through an option exercise at $8.43 per share and then sold 1,500 shares at $39.80 per share. These prices come from the reported option conversion terms and subsequent Common Stock sale entry.

How many Immunovant (IMVT) stock options does Atul Pande hold after this filing?

After exercising options for 1,500 shares, he is reported as holding 66,681 stock options of this award. This figure appears as the total derivative securities following the transaction for the Stock Option (right to buy) entry.

Does Atul Pande have any indirect holdings of Immunovant (IMVT) shares?

Yes. The filing shows 20,000 Common Shares held indirectly by a trust. This position is reported as a holding entry with indirect ownership classified as “By Trust,” separate from his directly held securities.

Were the Immunovant (IMVT) insider transactions made under a Rule 10b5-1 plan?

Yes. A footnote states the reported transactions occurred under a Rule 10b5-1 Plan adopted on December 26, 2025. The filing’s Rule 10b5-1 checkbox is also marked as affirmed for these transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pande Atul

(Last)

(First)

(Middle)

C/O IMMUNOVANT, INC.

1000 PARK FORTY PLAZA, SUITE 210

(Street)

DURHAM

NORTH CAROLINA

27713

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/24/2026		M⁽¹⁾		1,500	A	$8.43	118,231	D
Common Stock	07/24/2026		S⁽¹⁾		1,500	D	$39.8	116,731	D
Common Stock								20,000	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$8.43	07/24/2026		M⁽¹⁾			1,500	⁽²⁾	11/19/2029	Common Stock	1,500	$0	66,681	D

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.

2. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	/s/ Tiago Girao, attorney-in-fact for Atul Pande	07/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR